Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification

For the first time a section appeared for staging of non-organ retroperitoneal tumors in the UICC TNM classification 8th edition. Aim.To assess the prognostic significance of the TNM classification eighth edition for the most common retroperitoneal tumors-liposarcoma. Materials and methods.The distribution of patients by stages and survival in accordance with the TNM-8 classification were studied in192 patients with retroperitoneal non-organ liposarcoma (RLPS). Results.In the TNM-8 classification, only the degree of malignancy of the tumor has a prognostic value, and the T-category does not reflect the actual size of the RLPS and is considered T4 in 93%, which leads to inadequate staging. During the 15-year period, there were no cases with stages II and IIIA, and the survival rate was estimated only in patients with stages I and IIIB. A TNM classification with new values of the T-category was proposed, which demonstrated a more adequate distribution of patients by stages and the reliability ofintergroup differences in the survival rate. Conclusion.It is advisable to create a special TNM classification for RLPS, which makes up more than half of all retroperitoneal sarcomas.

Download Full-text

147P Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?

Annals of Oncology ◽

10.1016/j.annonc.2020.10.168 ◽

2020 ◽

Vol 31 ◽

pp. S1298

Author(s):

H. Watanabe

Keyword(s):

Tnm Classification ◽

Clinical Stage ◽

Cancer Control ◽

Type Ii ◽

Siewert Type ◽

Siewert Type Ii ◽

8Th Edition

Download Full-text

Updates in the 8th edition of the TNM staging system for esophagus and esophagogastric junction cancer

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyaa082 ◽

2020 ◽

Vol 50 (8) ◽

pp. 847-851 ◽

Cited By ~ 1

Author(s):

Hiroyuki Daiko ◽

Ken Kato

Keyword(s):

Esophagogastric Junction ◽

Tnm Classification ◽

Cancer Control ◽

Main Tool ◽

Staging System ◽

Tumor Location ◽

Tnm Staging ◽

7Th Edition ◽

Definition Of ◽

8Th Edition

Abstract The tumor–node metastasis (TNM) classification, originally developed in 1943 and subsequently adopted by the Union for International Cancer Control and the American Joint Committee on Cancer, is regularly updated based on new information and developments. The TNM classification system is the main tool used for both clinical and pathological staging of cancers worldwide. The 8th edition of the TNM classification for esophageal and esophagogastric junction (EGJ) cancer, released in 2017, was updated from the 7th edition based on additional data supplied by the Worldwide Esophageal Cancer Collaboration group. We summarize the main changes between the 7th and 8th editions of this TNM classification. Notable changes included separate clinical, pathological and pathological prognostic staging for adenocarcinomas and squamous cell carcinomas. Pathological prognostic staging was also improved by updating the T- and N-factors regarding histopathological differentiation and tumor location, respectively. The definition of EGJ cancer was changed from tumors centered within 5 cm to tumors within 2 cm of the EGJ. These updates to the TNM classification will help to improve the personalized management and treatment of patients with esophageal and EGJ cancers.

Download Full-text

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

The Journal of Urology ◽

10.1016/s0022-5347(18)30643-8 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 130-130

Author(s):

Markus Graefen ◽

Jochen Walz ◽

Andrea Gallina ◽

Felix K.-H. Chun ◽

Alwyn M. Reuther ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Cancer Control ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer

Download Full-text

PET/CT WITH 68GA-PSMA-11 IN DETECTION OF PRIMARY TUMOR AND RECURRENCE OF PROSTATE CANCER

Problems in oncology ◽

10.37469/0507-3758-2018-64-6-799-804 ◽

2018 ◽

Vol 64 (6) ◽

pp. 799-804

Author(s):

Darya Ryzhkova ◽

M. Poyda

Keyword(s):

Prostate Cancer ◽

Primary Tumor ◽

Biochemical Recurrence ◽

Whole Body ◽

Negative Results ◽

Primary Prostate Cancer ◽

Pet Ct ◽

The Relationship ◽

Positive Results ◽

T Category

Purpose: To study the diagnostic value of PET-CT with 68Ga-PSMA-11 in the diagnosis of a primary prostate cancer, preoperative staging, and the detection of recurrence of prostate cancer (PCa). Methods: 28 patients aged 64.7 ± 8.74 years were included. 10 patients primary prostate cancer, and 18 patients with biochemical recurrence of the disease after radical treatment were examined. All patients underwent PET-CT with 68Ga-PSMA-11 according the whole body protocol. Interpretation of images was performed visually and quantitatively by calculation of SUL max. Results: High focal or diffuse 68Ga-PSMA-11 uptake was found in prostate parenchyma in patients with primary prostate cancer. Additionally metastases in regional lymph nodes were diagnosed in 4 patients and bone metastases were found in one patient. The correlation between 68Ga-PSMA-11 uptake level and Gleason index in the primary tumor (R Spearmen = 0.25, p = 0.57) was not observed. PET-positive results were obtained in 14 patients and PET-negative results in 4 patients with biochemical recurrence of PCa. The relationship between the frequency of PET-positive results and Gleason index was not revealed (R Spearmen = 0.2, p = 0.39). We found a weak but significant correlation between the frequency of PET-positive results and the prostate tumor stage according to the T category (R Spearmen = 0.49, p = 0.049). In patients with low values of PSA (less than 1.0 ng/ml) in 4 out of 9 cases, PET-negative results were obtained. In patients with PSA level more than 1.0 ng/ml PET-positive results were obtained in all cases. Conclusions: PET/CT with 68Ga-PSMA-11 allows to diagnose the primary prostate cancer, to establish the stage of the disease in categories N and M, and also to determine the localization and dissemination of the tumor in patients with biochemical recurrence of prostate cancer. The relationship between 68Ga-PSMA-11 uptake in primary tumor and Gleason index was not found. The probability of obtaining PET-positive results in cases of biochemical recurrence is affected by a PSA level above 1 ng/ml and a high stage of the disease according to the T category (T3-T4).

Download Full-text

The AJCC 8th edition no longer substages pT2 prostate cancer: Does extent of tumor involvement not matter?

European Urology Supplements ◽

10.1016/s1569-9056(19)30158-7 ◽

2019 ◽

Vol 18 (1) ◽

pp. e216

Author(s):

R.S. Pompe ◽

F. Preisser ◽

S. Leyh-Bannurah ◽

P. Gild ◽

G. Salomon ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Involvement ◽

8Th Edition

Download Full-text

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

International Journal of Molecular Sciences ◽

10.3390/ijms22084109 ◽

2021 ◽

Vol 22 (8) ◽

pp. 4109

Author(s):

Mankgopo M. Kgatle ◽

Tebatso M. G. Boshomane ◽

Ismaheel O. Lawal ◽

Kgomotso M. G. Mokoala ◽

Neo P. Mokgoro ◽

...

Keyword(s):

Prostate Cancer ◽

T Cell ◽

T Cell Activation ◽

Cell Activation ◽

Cytotoxic T Lymphocyte ◽

Cancer Control ◽

Lymphocyte Activation ◽

Immune Checkpoints ◽

Mortality And Morbidity ◽

Domain 3

Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificant clinical benefits in the treatment of advanced prostate cancer (PCa) especially when they are used as monotherapies. Current existing PCa treatment initially offers an improved clinical outcome and overall survival (OS), however, after a while the treatment becomes resistant leading to aggressive and uncontrolled disease associated with increased mortality and morbidity. Concurrent combination of the ICIs with radionuclides therapy that has rapidly emerged as safe and effective targeted approach for treating PCa patients may shift the paradigm of PCa treatment. Here, we provide an overview of the contextual contribution of old and new emerging inhibitory ICs in PCa, preclinical and clinical studies supporting the use of these ICs in treating PCa patients. Furthermore, we will also describe the potential of using a combinatory approach of ICIs and radionuclides therapy in treating PCa patients to enhance efficacy, durable cancer control and OS. The inhibitory ICs considered in this review are cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1), V-domain immunoglobulin suppressor of T cell activation (VISTA), indoleamine 2,3-dioxygenase (IDO), T cell Immunoglobulin Domain and Mucin Domain 3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), B7 homolog 3 (B7-H3) and B7-H4.

Download Full-text